Hereditary spastic paraplegia (clinical cases)
Year: 2022, volume 18 Issue: №1 Pages: 97-102
Heading: Тhematic supplement Article type: Case report
Authors: Akhmadeeva L.R., Izhbuldina K.R., Gizatullin R.R., Derevyanko Kh.P., Sharipova A.Sh., Akhmadeeva E.N.
Organization: Bashkir State Medical University of the Russian Health Care
Heading: Тhematic supplement Article type: Case report
Authors: Akhmadeeva L.R., Izhbuldina K.R., Gizatullin R.R., Derevyanko Kh.P., Sharipova A.Sh., Akhmadeeva E.N.
Organization: Bashkir State Medical University of the Russian Health Care
Summary:
In this paper, we present three clinical cases of patients whom we observed with genetically proven familial cases of hereditary spastic paraplegia caused by mutations in SPG4 gene. We give detailed clinical descriptions, pedigrees and discuss these patients comparing them with data published in Russian and international journals. The considered clinical cases attract attention with manifestations that are not often encountered in practice (cognitive deficiency, limbs malformations), and demonstrate additional possibilities for symptomatic relief using botulinum toxin therapy to alleviate muscle spasticity in the legs. All patients registered a positive effect.
Keywords: hereditary spastic paraplegia
Bibliography:
1. Phenotypic Series — PS303350. URL: https://omim.org/ phenotypicSeries/PS303350 (20 March 2022).
2. Rudenskaya GE, Kadnikova VA, Ryzhova OP. Common forms of hereditary spastic paraplegias. S.S. Korsakov Journal of Neurology and Psychiatry 2019; (2): 94-104
3. Veytsman В, Akhmadeeva L. ТЕХ in the GLAMP world: On-demand creation of documents online. TUGboat2010; 31 (2): 236-40.
4. Shribman S, Reid E, Crosby AH, et al. Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches. Lancet Neurol 2019; 18 (12): 1136.
5. Fink JK. Hereditary spastic paraplegia: clinical pathologic features and emerging molecular mechanisms. Acta Neuropathol 2013; 126(3): 307-28.
6. Chelban V, Tucci A, Lynch DS, et al. Truncating mutations in SPAST patients are associated with a high rate of psychiatric comorbidities in hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry 2017; (88): 681.
7. Diniz de Lima F, Faber I, Servelhere KR, et al. Randomized trial of botulinum toxin type A in hereditary spastic paraplegia — the SPASTOX trial. Mov Disord 2021; 36 (7): 1654-63.
8. Kislyakova EA,Zakharova DA. Effectiveness of botulinum toxin therapy in Strumpel disease. Smolenskiy meditsinskiy al'manakh 2021; (1): 150-4.
9. Paparella G, Vavla М, Bernardi L, et al. Efficacy of a combined treatment of botulinum toxin and intensive physiotherapy in hereditary spastic paraplegia. Front Neurosci 2020; (4): 111.
10. Jacinto-Scudeiro LA, Dariva Machado G, Ayres A, et al. Are cognitive changes in hereditary spastic paraplegias restricted to complicated forms? Front Neurol 2019; (10): 508.
| Attachment | Size |
|---|---|
| 2022_01-1_097-102.pdf | 474.51 KB |
Русский
English